You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
江中藥業(600750.SH):擬以股權轉讓及增資取得海斯製藥51%股權
格隆匯 09-17 16:38

格隆匯9月17日丨江中藥業(600750.SH)公佈,公司股權轉讓及增資的方式收購晉城海斯製藥有限公司(“海斯製藥”)51%的股權;其中通過公開摘牌方式取得海斯製藥36%股權(晉能控股裝備製造集團有限公司持有海斯製藥25.7102%股權晉城王台科工貿有限公司持有海斯製藥10.2898%股權)成功,後續計劃通過增資方式將有海斯製藥的股權比例由36%增加51%此次交易價款總金額預計22023.4338萬元,資金來源為公司自有資金(最終交易價格以實際成交價格為準)

公吿顯示,海斯製藥主要從事化學藥的研製,以治療型化藥為主,具備生產生物製劑、口服固體制劑、小容量注射劑、凍乾粉針劑、膠囊劑、顆粒劑等劑型和原料藥的生產條件。公司核心產品貝飛達雙歧桿菌三聯活菌腸溶膠囊雷貝拉唑鈉腸溶片注射用鹽酸溴已注射用伏立康唑其中,OTC 產品貝飛達雙歧桿菌三聯活菌腸溶膠囊國家基藥目錄、國家醫保目錄產品主治因腸道菌羣失調引起的急慢性腹瀉、便祕據米內網數據,“貝飛達雙歧桿菌三聯活菌腸溶膠囊2020 年銷售額國內微生態製劑排名第4

交易完成後,利於藉助海斯製藥產品豐富公司產品結構,完善公司胃腸領域業務佈局方在品牌、產品、終端等方面的廣泛協同和資源整合提升公司盈利能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account